Relmada Therapeutics Inc
relmada.comWhat Do They Do?
Develops investigational drug candidates for people with bladder cancer and neurological disorders.
10-K for FY2025, filed Mar 19, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$12.9MView ↗
- ▲ +31% (Loss)
- vs −$9.9M in Q2 FY2025
Pipeline focus
The earlier report focused on esmethadone for depression. The latest centers on a bladder cancer candidate and a neurosteroid for neurological disorders, and says work on esmethadone has ended.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 19, 2026Relmada Therapeutics, Inc. (Relmada, the Company, we or us) (a Nevada corporation), is a publicly traded, clinical-stage biotechnology…View ↗
Currently, our lead product, NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is…View ↗
Our second product, sepranolone is a novel neurosteroid epimer of allopregnanolone. Sepranolone is being developed for the potential…View ↗
Loading...
